HYBRID EVENT: You can participate in person at Valencia, Spain or Virtually from your home or work.
Radiolabelled Drugs

The use of Radioisotopes is important in pharmaceutical research and development (R&D). They are frequently used in non-clinical and clinical studies for the development of compounds for different therapeutic areas, such as central nervous system (CNS) diseases (e.g., Dementia, Alzheimer’s disease (AD), and Parkinson’s disease), oncology, and metabolic diseases (e.g., diabetes mellitus). Pharmaceutical companies invest a lot of time and money in research on new treatment strategies for diseases with a high medical need, such as oncology and metabolic diseases. A large number of drugs fails during development due to toxicity and/or the lack of efficacy (Kola, I, 2008). Several attempts are being made to improve this, such as obtaining a better understanding of the pathophysiology of diseases, development of robust animal models, the application of biomarkers, development of pharmacokinetic (PK) - pharmacodynamic (PD) models, and the application of non-invasive techniques such as positron emission tomography (PET) in an early stage of development.

Committee Members
Speaker at Pharmaceutical Conference - Consolato M Sergi

Consolato M Sergi

Universities of Alberta and Ottawa, Canada
Speaker at Drug Delivery Events - Vladlen Slepak

Vladlen Slepak

University of Miami Miller School of Medicine, United States
Speaker at Drug Delivery Events -  Andreas M Papas

Andreas M Papas

Antares Health Products, United States
Speaker at Drug Delivery Events - Sergey Suchkov

Sergey Suchkov

The Russian University of Medicine and Russian Academy of Natural Science-Moscow, Russian Federation

Submit your abstract Today

Watsapp